University Hospital for Tumors, University Hospital Center Sestre milosrdnice
Abstract
Tamoxifen, a triphenylethyleneestrogen receptor modulator, is an eff ective treatment for estrogen receptor positive breast cancer patients. It acts as an estrogen antagonist in breast tissue and a week estrogen agonist in the female genital tract. Its estrogenagonist properties refl ects on increased risk of gynaecologic pathologies and includes the development of
endometrial cancer, endometrial hyperplasia, endometrial polyps, adenomyosis, leiomyomas, uterine sarcomas, cervical polyps and ovarian cysts. Breast cancer patients during tamoxifen treatment should be under close gynaecological and ultrasonographic surveillance.Tamoxifen, trifeniletilenski modulator estrogesnih receptora, se koristi u liječenju raka dojke s pozitvnim estrogenskim receptorima. U tkivu dojke i tumorskim stanica ima estrogen-antagonistički učinak, a u ženskom spolnom sustavu blagi agonistički učinak što se očituje povećanim rizikom od ginekoloških bolesti koje uključuju rak endometrija, hiperplaziju
endometrija, polipe endometrija, adenomiozu, miome, sarkome, polipe vrata maternice i ciste jajnika. Bolesnice s rakom dojke koje se liječe tamoxifenom trebaju biti redovito ginekološki i ultrazvučno pregledavane
